Figure 6. Exploring the mechanism of KRAS-related immune alteration. (A) 12 of the 19 HLA genes showed significantly lower expression levels in the KRAS-mutated group compared to the wild-type group. (B) The expression of 7 checkpoint-related genes (BTLA, CD80, CD86, CTLA4, IDO1, PDCD1LG2, and TIGIT) were lower in the KRAS-mutated group (* P<0.05, ** P<0.01, *** P<0.001). (C) Comparison of TMB between the KRAS-mutated and wild-type groups. (D) Spearman correlation analysis between 10 KRAS-related signaling pathways and 30 immune signatures.